Month: September 2024

Security Papers Limited Reports Strong Fiscal Year Performance

Karachi: Security Papers Limited (SPL) has released its Annual Report, detailing significant growth in financial performance for the fiscal year ending June 30, 2024. The company reported a record high in both revenue and profits, with total income re…

Al-Ghazi Tractors Announces New Board Appointment

Karachi: Al-Ghazi Tractors Limited has officially appointed Ms. Samiha Zahid as an Independent Director, effective September 5, 2024, replacing Ms. Farah Qureshi who previously held the position.

This appointment fills a casual vacancy on the Board …

Sindh Modaraba to Review Annual Accounts in Upcoming Board Meeting

Karachi: The Board of Directors of Sindh Modaraba will convene on September 11, 2024, to review the company’s annual accounts for the period ended June 2024 and to discuss potential entitlement declarations. According to information available from the…

SECP Launches Survey to Boost Islamic Capital Market Development

Islamabad: The Securities and Exchange Commission of Pakistan (SECP) has initiated a comprehensive Knowledge, Attitude, and Practices (KAP) study aimed at enhancing the Islamic Capital Market. Announced on September 4, 2024, this survey seeks to asses…

Fateh Textile Mills Faces Extended Trading Suspension on PSX

Karachi: The Pakistan Stock Exchange (PSX) has announced a continued suspension of trading in shares of Fateh Textile Mills Limited, effective from September 5, 2024. This decision follows the company’s failure to address several non-compliances with …

Music Licensing, Inc. (OTC: SONG) Announces Acquisition of Royalty Rights to “Thank God I Got It” by Desiigner, Bolstering Its Diverse and Star-Studded Portfolio

NAPLES, Fla., Sept. 03, 2024 (GLOBE NEWSWIRE) — Music Licensing, Inc. (OTC: SONG), a leading entity in the music industry, is excited to announce the acquisition of the royalty rights to “Thank God I Got It” by the renowned artist Desiigner. This acquisition underscores Music Licensing, Inc.’s commitment to diversifying

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies. SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage